The Alliance for Regenerative Medicine Announces 2018 Cell & Gene Meeting on the Mesa
May 30, 2018
The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced it will hold its annual Cell & Gene Meeting on the Mesa this year on October 3-5, 2018 in La Jolla, California. This year’s event is expected to attract more than 1,000 attendees, including senior executives from leading cell therapy, gene therapy and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations and disease philanthropies, life science media and more.
The Alliance for Regenerative Medicine and Informa Pharma Intelligence to Host Regenerative Medicine Advanced Therapy Designation Webinar on June 13, 2018
May 29, 2018
The Alliance for Regenerative Medicine (ARM) today announced it will co-host a webinar titled “RMAT Designation – Impact on the Regenerative Medicine Sector & How it Compares to Other Accelerated Approval Programs.” During this one-hour live event, Michael Werner, Co-founder and Senior Policy Counsel for ARM will be joined by Tim Miller, President & Chief Scientific Officer of Abeona Therapeutics; Gil Van Bokkelen, CEO of Athersys; and Alvin Shih, CEO of Enzyvant Therapeutics to discuss the Regenerative Medicine/Advanced Therapy (RMAT) designation and its significance. Each company will detail its experience in obtaining the designation and its impact on their product development program. The discussion will be moderated by Amanda Micklus, Principal Analyst of Pharma Intelligence at Informa. Patricia Reilly, VP of Pharma Intelligence, will introduce the topic with a primer on the RMAT designation.
The Alliance for Regenerative Medicine Applauds FDA's Actions Against Unregulated Stem Cell Clinics
May 15, 2018
The Alliance for Regenerative Medicine, along with sector colleagues ISCT and ISSCR, applauds last week’s actions by the FDA to stop two unregulated stem cell clinics from marketing and delivering unapproved stem cell products, and for violating current good manufacturing practice requirements. Such action is necessary to protect the health and safety of patients from unscrupulous actors touting unproven clinical benefits, maintaining insufficient sterility standards, and worse.